Skip to content
Cultural Foundation
Author:
AtaiBeckley Inc.
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026
May 27, 2026
AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update
May 12, 2026
AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder
April 23, 2026
AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs
April 8, 2026
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst
March 24, 2026
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
March 10, 2026